Invanz 1g bubuk injeksi MSD ngobati infeksi rata-rata nganti abot (15ml)

Bentuk sediaan kothak
Spesifikasi Ertapenem

Komposisi

Informasi komposisi	Isi
Ertapenem	1g

Migunakake

indications Invanz drugs are indicated in the following cases: Invanz is indicated to treat medium to serious bacterial infections due to these antibiotic sensitivity, as well as the initial treatment according to experience before identifying the pathogenic bacteria in the following infections: Infectious abdominal infections; abortion infections, gynecological infections after surgery; bacterial infection. Pharmacological Ertapenem has anti -vitro anti -energy and anaerobic bacteria, both gram -positive and gram negative. Ertapenem's bactericidal effect is due to the synthesis of bacterial walls: Ertapenem attaches to penicillin (PBP) proteins. In E.coli, Ertapenem has strong affinity for PBP La, 1B, 2, 3, 4 and 5, mainly with PBP2 and PBP3. Ertapenem is very sustainable, not hydrolyzed by most ß-lactamase types, including penicillinase, cephalosporinase and ß-lactamase broad spectrum but not against metallo-ß-lactamase. Invanz has the activity against most of the following bacteria both in vitro and in clinical infections (see indicators): Gram -positive and anaerobic bacteria: Staphylococcus aureus - Staphylococcus aureus (including penicillinase strain); Streptococcus agalactiae; Invanz resistant methicillin. Many of Enterococcus Faecalis and most Enterococcus Faecium strains are also resistant to Invanz. Gram -negative and anaerobic bacteria: Escheria coli; Haemophilus Influenzae (including ß-lactamase strain); Gas: Bacteroides Fragilis and other species in group B. Fragilis; Clostridium species (except C. Difficile); Prevotella. The minimum inhibitory concentration (mic) Invanz of Invanz is ≤ 1 mcg/ml for the majority (≥ 90%) The strains of the streptococcus include Streptococcus pneumoniae, concentration ≤ 0.5 mcg/ml against the majority (≥ 90%) of Haemophilus strains, ≤ 2 mcg/ml resistant to large parts (≥ ≥ ≥ ≥ ≥ ≥ ≥ ≥ ≥ ≥ ≥ 90%) Mandatory and concentration ≤ 4 mcg/ml are against most (≥ 90%) strains of mandatory anaerobic bacteria in the list below; However, the effect and safety of Invanz in the treatment of clinical bacterial infections due to the infection of the above bacteria has not been proved in clinical studies with good and appropriate control: Gram -positive and anaerobic bacteria: Staphylococcus, negative coagulase, sensitive to methicillin; Streptococcus pneumoniae resistant penicillin; Many Enterococcus Faecalis strains and most Enterococcus Faecium strains are also resistant to Invanz. Gram -negative and anaerobic bacteria: citrobacter Freundii; Oxytoca; penicillin, cephalasporin (including the third generation) and aminoglycosides but are sensitive to Invanz. Anaerobic bacteria: Fusobacterium. Clinical studies Adults Ertapenem has been evaluated in a clinical trial in 665 adults treating infections in the abdominal cavity with complications: comparing Ertapenem (once a day 1 g of intravenous infusion) with piperacillin/tazobactam (intravenous 3.375 g every 6 hours), used for 5-14 days. At 1-2 weeks after the treatment period, the clinical and microbiological success rate is 89.6% (190/212) with Ertapenem and 82.7% (162/196) with piperacillin/lazobactam; After 4-6 weeks of treatment (evaluation), the success rate is 86.7% (176/203) with ERTAPENEM and 81.3% (157/193) with Piperacillin/Tazobactam. In clinical trials, Ertapenem evaluation in 540 adults treating dermatitis and complicated skin structure, comparing Ertapenem (daily intravenous infusion 1 g) with piperacillin/tazobactam (intravenous infusion every 6 hours; each time 3.375 g) for 7-14 days, including lower limb infection due to diabetes, soft tissue infection, bacteria Pus drainage. The clinical success rate in 10-21 days after the treatment period (evaluation) is 82.2% (152/185) with ERTAPENEM and 84.5% (147/174) with Piperacillin/Tazobactam. Ertapenem is evaluated effectively in the treatment of diabetes with diabetes in a clinical test with control, double blindness, multicolored, random groups. This study compares (1 g IV once a day) with piperacillin/tazobactam (3,375 g IV every 6 hours) on 586 patients. Both treatment regimen allows to switch to amoxicillin/clavuclanate therapy with oral treatment with a total treatment time of 5-28 days (both injection and orally). The clinical success rate within 10 days after treatment is 87.4% (180/206) for Ertapenem and 82.7% (162/196) for piperacillin/tazobactam. In two clinical trials on 866 adults treating pneumonia in the community, Ertapenem (once a day injected 1 g) is compared to Ceftriaxone (1 g in injection a day). Both regimen allows to switch to amoxicillin/clavulanate therapy with oral treatment with a total treatment time of 10-14 days (both injection and oral). The clinical success rate (2 studies) at 7-14 days after the treatment period (evaluation) is 92% (335/364) with ERTAPENEM and 91.8% (270/294) with Ceftriaxone. In two clinical trials on 850 adults treating complicated urinary tract infections, including nephritis - pyelonephritis, Ertapenem (daily injection 1 g) is compared to ceftriaxone (once a day 1 g). Both regimen allows to switch to oral ciprofloxacin (500 mg, taken 2 times a day) with a total treatment time of 10-14 days (both injection and oral). Microbiological success rate (2 studies) at 5-9 days after the treatment period (evaluation) is 89.5% (229/256) with Ertapenem and 91.1% (204/224) with Ceftriaxone. In a clinical trial, Ertapenem evaluation (1 g intravenously, once a day) compared to piperacillin/ tazobactam (3,375 g of intravenous injection every 6 hours) used for 3-10 days in the treatment of higher level pelvic inflammatory disease of 412 adults including 350 infected people at birth/ after birth and 45 infections. The clinical success rate in 2-4 weeks after the treatment period (evaluation) is 93.9% (153/163) with Ertapenem and 91.5% (140/153) with Piperacillin/Tazobactam. A multi -center test, double blindness, random groups to evaluate the effectiveness of the surgery in over 1002 adults, compare Invanz IV (1 g) with Cefotetan IV (2 g) of the infusion lasting 30 minutes at 1 hour before colorectal surgery under the program. The beneficial clinical response rate in general 4 weeks after surgery (the main criterion is effective) is 72.0% for the patient group using Ertapenem (N = 338) and 57.2% in the group using cefotetan (n = 334) (difference 14.8%, [95% Ci is 7.5% -21.9%]), showing the outstanding effect Colorectal surgery by program. Children Ertapenem is assessed in two multi -central, double clinical trials, random subgroups on children from 3 months to 17 years old. The first test is admitted 404 children, comparing Ertapenem (15 mg/kg intravenously every 12 hours on children from 3 months to 12 years old and 1g of intravenous infusion once a day for children 13 years old to 17 years old) with ceftriaxone (50 mg/kg/day of intravenous transmission 2 times on dual disease from 3 months to 12 years old and 50 mg/kg/day daily infection from 17 years old) There are complications, skin and soft tissue infections or pneumonia in the community. Both regimen allow to switch to oral amoxicillin/clavulanate with a total time of 14 days (injection and oral). Bacterial success rate is assessed in a protocol -based analysis in urinary -infected children with complications that is 87.0% (40/46) for Ertapenem and 90.0% (18/20) for Ceftriazone. The success rate in a protocol -based analysis in children treated with skin and soft tissue is 95.5% (64/67) for Ertapenem and 100% (26/26) for ceftriaxone and in patients received by the community is 96.1% (74/77) for Ertapenem and 96.4% (27/2) for 27/28) for 27/28) ceftriaxone. The second test is admitted 112 children and compares Ertapenem (15 mg/kg intravenously every 12 hours on patients from 3 months to 12 years old and LG intravenously once a day on children from 13 years old to 17 years old) with ticarcillin/clavulanate (50 mg/kg for children 60 kg, 6 times or 6 days) Acute pelvic and infections. On patients treated with complications of abdominal infections (those who have previously had a hole or appendicitis with complications) clinical success rate of 83.7% (36/43) for Ertapenem and 63.6% (7/11) for Ticarcillin/Clavulanate in an analysis based on protocol. On patients treated for acute pelvic infections (postoperative or endometritis spontaneous or abortion infection) of clinical success rate of 100% (23/23) for Ertapenem and 100% (4/4) for Ticarcillin/Clavulanate in an analysis based on protocol. Dynamic pharmacokinetics absorption Ertapenem injection mixed with 1% lidocaine injection solution (American pharmacopoeia) mixed in salt water without epinephrine, is easy to absorb after intramuscular injection with the recommended dose of 1 g. The average bioavailability is about 92%. After an intramuscular injection of 1 g/day, the average peak concentration in plasma (cmax) reaches about 2 hours (TMAX). Distribution Ertapenem is heavily associated with blood protein. In healthy young adults, Ertapenem's protein cohesion will decrease as plasma concentrations increase. When plasma concentration

Sadurunge njupuk Invanz 1g bubuk injeksi MSD ngobati infeksi rata-rata nganti abot (15ml)

Cara nggunakake

pasien umur 13 taun utawa luwih

Siapke solusi intravena

Aja nyampur utawa ngirim Invanz karo obat liyane.

Aja rekonsiliasi karo solusi sing ngemot Dexrose (α-D-glukosa).

Perlu mbalekake lan ngencerake Invanz sadurunge injeksi.

Gunakake 10 ml saka salah sawijining pelarut ing ngisor iki, pompa menyang bokor Invanz 1 g kanggo rekonsiliasi: Banyu sing dicampur karo injeksi, larutan injeksi NaCl 0,9% utawa banyu injeksi alkalin. Solusi intramuskular
Perlu mbalekake Invanz sadurunge injeksi.
1. Periode 1 g Invanz kanthi 3,2 ml larutan injeksi lidocaine 1% utawa 2% (ora ana epinefrin). Goyangake toples kanthi apik kanggo mbubarake obat kasebut.
  Bocah-bocah umur 3 wulan nganti 12 taun
  Siapke solusi intravena
  Aja nyampur utawa ngirim Invanz karo obat liyane.
  Aja rekonsiliasi karo solusi sing ngemot Dexrose (α-D-glukosa).
  Perlu mbalekake lan ngencerake Invanz sadurunge injeksi.
  1. Gunakake 10 ml saka salah sawijining pelarut ing ngisor iki sing dipompa menyang vial Invanz 1 g kanggo ngolah maneh: banyu sing disuntikake, larutan injeksi NaCl 0,9% utawa banyu injeksi alkalin. liyane.
    Perlu mbalekake Invanz sadurunge injeksi.
    1. Periode 1 g Invanz kanthi 3,2 ml larutan injeksi lidocaine 1% utawa 2% (ora ana epinefrin). Goyangake jar kasebut kanthi teliti kanggo mbubarake obat kasebut. Hey.
      Obat injeksi kudu dites kanthi ati-ati kanthi mripat kanggo ndeleng apa ana barang aneh utawa owah-owahan warna sadurunge digunakake. Solusi Invanz saka ora ana warna nganti kuning cahya. Yen owah-owahan warna ing kisaran iki, ora ana pengaruh ing efektifitas obat kasebut.
      Dosis
      
      Dosis biasa Invanz ing pasien saka 13 taun lan luwih lawas yaiku 1 g, sapisan dina. Dosis biasa Invanz ing bocah-bocah saka 3 sasi nganti 12 taun yaiku 15 mg/kg, 2 kali dina (ora luwih saka 1 g/dina).
      Bisa intravena utawa intramuskular. Yen nggunakake jalur intravena, wektu intravena kudu luwih saka 30 menit.
      Bisa intramuskular tinimbang infus intravena Invanz, kanggo nambani infeksi mung kudu intramuskular.
      Wektu perawatan karo Invanz biasa yaiku 3-14 dina, nanging beda-beda gumantung saka jinis infeksi, lan bakteri patogen (deleng sing dituduhake). Yen indikasi klinis, bisa diowahi dadi antibiotik oral nalika didandani ing alas.
      Ing studi klinis kontrol, pasien diobati sajrone 3 nganti 14 dina. Suwene suwene wektu perawatan amarga keputusane dokter perawatan adhedhasar posisi lan keruwetan infeksi lan respon klinis pasien. Ing sawetara panaliten, dhokter mutusake kanggo nransfer perawatan menyang antibiotik oral sawise ndeleng perbaikan klinis.
      Infeksi pencegahan ing wong diwasa sawise operasi kolorektal ing program operasi: Kanggo nyegah infeksi lokal sawise operasi kolorektal miturut program kasebut, dosis sing disaranake yaiku 1 g transmisi intravena, mung 1 jam sadurunge operasi.
      Kanggo wong sing gagal ginjel: Invanz bisa digunakake kanggo nambani infeksi kanggo wong sing gagal ginjel. Kanggo pasien kanthi pemurnian kreatinin> 30 ml / min / 1,73 m2, ora perlu nyetel dosis. Nanging kanggo wong diwasa, gagal ginjal saya maju (pemurnian bun
      Kanggo wong sing lagi hemoglobin: Ing studi klinis, sawise infus intravena dosis siji 1 g Ertapenem sadurunge pembuahan, kira-kira 30% saka dosis ditemokake ing mitosis. Nalika nggunakake Invanz dosis 500 mg / dina kanggo 6 jam sadurunge evaluasi ing pasien diwasa, dosis 150 mg kudu ditambahake sawise pupuk rampung. Nanging yen sampeyan wis nggunakake Invanz paling sethithik 6 jam sadurunge evaluasi, ora perlu dosis tambahan. Ora ana data ing pasien karo dialisis utawa pupuk weteng. Ora ana data babagan bocah sing ngalami hemolisis.
      Yen mung kreatinin - konsentrasi getih, gunakake rumus cockcroft lan gault "kanggo nemtokake pemurnian kreatinin.
    2. Lanang: [bobot (kg) x (140 - umur miturut taun)]/[(72) x Serum kreatinin (mg/100 ml)]. (Deleng farmakokinetik, karakteristik pasien, gagal ati).
      Dosis Invanz ora gumantung saka umur (13 utawa luwih) utawa jender.
      Cathetan: Dosis ing ndhuwur mung kanggo referensi. Dosis spesifik gumantung saka kahanan lan tingkat kemajuan penyakit kasebut. Kanggo dosis sing cocog, sampeyan kudu takon dhokter utawa spesialis medis.Apa sing kudu ditindakake nalika overdosis? Meh ora ana kasus sing sengaja overdosis Invanz. Ora ana keracunan sing signifikan ing sukarelawan diwasa sing sehat ing 3 g Invanz saben dina, suwene 8 dina. Ing studi klinis ing wong diwasa, tangi saben dina nganti 3 g ora nyebabake reaksi penting ing klinis. Ing studi klinis ing bocah-bocah, kanthi intravena dosis siji 40 mg/kg nganti dosis maksimal 2 g ora beracun.
      Yen overdosis digunakake, Invanz kudu mandheg lan nambani dhukungan umum nganti obat kasebut diekskresi liwat ginjel.
      bisa ngeculake Invanz amarga hemolisis; Nanging, ora ana informasi babagan panggunaan hemolisis kanggo nambani overdosis iki.
      Yen ana darurat, langsung nelpon puskesmas 115 utawa menyang puskesmas sing paling cedhak.
      Apa sing kudu ditindakake yen sampeyan lali 1 dosis? Nanging, yen wektu kanggo ngendhokke karo dosis sabanjuré cendhak banget, skip dosis lan terus tanggalan tamba. Aja nggunakake dosis kaping pindho kanggo ngimbangi dosis sing ora kejawab.

Efek sisih

Nalika nggunakake Invanz, sampeyan bisa ngalami efek sing ora dikarepake (ADR) kayata:

Wong diwasa

Ing studi klinis, jumlah pasien Ertapenem luwih saka 1900, sing luwih saka 1850 pangguna Invanz dosis 1 g. Umume reaksi salabetipun dilaporake ing riset klinis kanthi tingkat entheng nganti medium. Reaksi Ertapenem kira-kira 20% pasien sing diobati karo Ertapenem. Mungkasi obat amarga reaksi umum sing gegandhengan karo obat ing 1,3% pasien.

Reaksi sing paling umum sing ana gandhengane karo obat nalika nggunakake Ertapenem yaiku diare (4.3%), komplikasi vena ing situs injeksi (3.9%), mual (2.9%), sirah (2.1%).

Sawise injeksi Ertapenem, ana reaksi ing ngisor iki sing gegayutan karo panggunaan obat:

kerep ketemu (≥ 1/100,

Gangguan sistem saraf: sirah;

Gangguan sistem saraf: pusing, ngantuk, insomnia, konvulsi, kebingungan.

Kelainan kulit lan jaringan: Ruam abang, gatel. 0,2% pangguna Ertapenem, ing 0,3% pangguna Piperacillin / Tazobactam lan ing 0% pangguna Ceftriaxone.

Ing mayoritas studi klinis, antibiotik sing disuntikake diterusake karo antibiotik oral (pirsani farmakologis, studi klinis). Sajrone periode perawatan lan periode ngawasi 14 dina sawise perawatan, reaksi sing ana gandhengane karo Invanz kalebu reaksi sing kasebut ing ndhuwur, uga ruam lan vaginitis kanthi tingkat 21,0% (umum) lan reaksi alergi, ora nyaman lan infeksi jamur kanthi tingkat> 0,1% nanging

Ing panaliten klinis babagan perawatan infeksi diabetes amarga diabetes ing 289 pasien diwasa diabetes sing diobati karo Ertapenem, karakteristik reaksi salabetipun umume padha karo reaksi sing diamati ing uji klinis sadurunge.

Ing panaliten klinis babagan panggunaan Invanz ing wawancara karo infeksi lokal sawise operasi kolorektal ing program liwat 476 pasien diwasa sing nggunakake 1 g Ertapenem sadurunge operasi, mung irama sinus minangka reaksi sing ora becik sing ana gandhengane karo obat sing durung katon ing uji klinis sadurunge sing wis dilaporake kanthi rasio> 0.1% nanging Ana total 384 pasien sing diobati karo Ertapenem ing uji klinis. Karakteristik safety sakabèhé obat ing bocah-bocah padha karo wong diwasa. Ing uji klinis, reaksi salabetipun klinis sing gegandhengan karo obat sing paling umum sajrone terapi dilaporake minangka diare (5,5%), nyeri ing situs injeksi (5,5%) lan eritema ing situs injeksi (2,6%).

Reaksi salabetipun ing ngisor iki kacarita nalika pasien ngobati Ertapenem:

utawa ketemu (1/100,

Kelainan gastrointestinal: diare, muntah

Kelainan lan kondisi umum ing situs injeksi: Ruam abang ing situs injeksi, nyeri ing situs injeksi, inflamasi intravena ing situs injeksi, bengkak ing situs injeksi. Invanz ing uji klinis) kalebu: botol atos ing situs injeksi, gatal ing situs injeksi, vena lan panas ing situs injeksi.

Ing studi klinis ing bocah-bocah, umume pasien diobati nganggo antibiotik injeksi lan banjur pindhah menyang antibiotik oral sing cocog. Sajrone perawatan lan wektu ngawasi 14 dina sawise perawatan, reaksi salabetipun sing gegandhengan karo obat ing pasien sing nggunakake Invanz padha karo reaksi sing kadhaptar ing ndhuwur.

Pengalaman purna jual

Reaksi salabetipun ing ngisor iki wis dilaporake nalika obat kasebut digunakake ing pasar:

Sistem kekebalan: Anafilaksis kalebu reaksi anafilaksis. werna.

Takon dokter babagan efek sing ora dikarepake nalika nggunakake obat.

Pènget

Sadurunge nggunakake obat kasebut, sampeyan kudu maca instruksi kasebut kanthi teliti lan deleng informasi ing ngisor iki.

Kontraindikasi

Obat Invanz dikontraindikasi ing kasus ing ngisor iki:

Hipersensitivitas kanggo komponen Invanz utawa karo antibiotik ing klompok sing padha utawa ing pasien sing duwe reaksi anafilaksis karo ß-laktam. HCI).

Ati-ati nalika nggunakake

Ana laporan reaksi hipersensitif sing serius, kadhangkala mati (anafilaksis) ing pasien sing duwe antibiotik ß-laktam. Reaksi kasebut luwih umum ing wong sing duwe riwayat hipersensitifitas marang akeh jinis alergen. Ana laporan babagan pasien sing duwe riwayat hipersensitivitas kanggo penisilin, ana uga reaksi hipersensitivitas serius nalika nggunakake ß-laktam liyane. Mulane, sadurunge nggunakake Invanz, perlu kanggo nliti pasien kanthi ati-ati babagan reaksi hipersensitivitas sadurunge karo penisilin, cephalosporin, B-Lactam liyane lan alergen liyane. Yen reaksi alergi marang Invanz, obat kasebut kudu mandheg langsung. Perlu ngobati perawatan darurat reaksi anafilaksis sing serius.

Kejang lan efek samping liyane ing sistem saraf pusat (CNS) wis dilapurake sajrone perawatan karo Invanz (deleng efek samping). Sajrone fase riset klinis ing pasien diwasa sing diobati karo Invanz (1 g sapisan dina), konvulsi, preduli saka apa ana hubungane karo obat kasebut utawa ora, kedadeyan ing 0,5% pasien sajrone perawatan lan 14 dina tindak lanjut. Efek samping iki paling umum ing pasien sing nandhang gangguan neurologis pusat (contone, karusakan otak utawa riwayat epilepsi) lan / utawa fungsi ginjel. Rekomendasi strictly tundhuk karo regimen dianjurake, utamané ing patients karo faktor sing dianggep mimpin kanggo kejang. Terapi anti-kejang kudu diterusake ing pasien kejang sing dikenal. Yen ana tremor lokal, geter otot, utawa konvulsi, pasien kudu ditaksir ing saraf lan mriksa dosis Invanz kanggo nemtokake manawa arep nyuda utawa mungkasi perawatan utawa ora.

Artikel ing ndhuwur babagan kasus individu nuduhake yen nggunakake carbapenem, kalebu Ertapenem bebarengan karo asam Valproic utawa sodium Divalproex bakal nyuda tingkat asam Valproic. Tingkat asam valproat bisa dikurangi luwih murah tinimbang interaksi iki, saéngga nambah risiko serangan kejang. Nambah dosis asam valproat utawa sodium divalproex bisa uga ora cukup kanggo ngatasi interaksi iki.

Umumé, ora dianjurake kanggo nggunakake asam natrium Valproic/Divalproex karo Ertapenem. Antibiotik bisa digunakake saliyane karbapenem kanggo ngobati infeksi ing pasien sing dikontrol kanthi sawan karo asam valproat utawa sodium divalproex. Yen perlu nggunakake Invanz, disaranake nggunakake terapi anti-seizure liyane (pirsani interaksi obat). Kaya antibiotik liyane, Invanz sing dawa bakal nambah proliferasi bakteri sing ora sensitif karo antibiotik iki. Perlu terus-terusan ngevaluasi kondisi kasebut. Yen superinfeksi kedadeyan sajrone perawatan, perawatan sing cocog kudu ditindakake.

Ana laporan babagan kolitis palsu, saka efek entheng nganti urip -etine ing umume antibiotik kalebu Ertapenem. Mulane, perlu dipikirake komplikasi iki nalika diagnosa pasien kanthi diare sawise njupuk obat antibakteri. Panaliten nuduhake yen racun sing disekresi saka Clostridium difficile minangka panyebab utama "kolitis antibiotik".

Ati-ati nalika Invanz intramuskular, supaya ora sengaja nyuntik menyang pembuluh getih (ndeleng dosis lan cara nggunakake).

Lidocaine HCI minangka pelarut kanggo injeksi intramuskular Invanz. Mangga deleng Lidocaine HCI.

Bocah-bocah

Keamanan lan efektifitas Invanz ing bocah-bocah saka 3 sasi nganti 17 taun wis dibuktekake liwat dokumen saka riset lengkap lan kontrol sing apik ing wong diwasa, data farmakokinetik ing bocah-bocah, lan data tambahan saka studi nggunakake obat kontrol liyane ing bocah-bocah saka 3 sasi nganti 17 taun kanthi infeksi ing ngisor iki (pirsani indikasi lan karakteristik pasien sing dinamis).

Infèksi abdominal infèksius.

Infeksi kulit lan komplikasi.

Ora ana rekomendasi kanggo nggunakake Invanz ing bocah-bocah ing umur 3 sasi amarga ora ana data.

Efek obat kasebut ing kemampuan nyopir lan ngoperasikake mesin

Ora ana data sing nuduhake yen Invanz mengaruhi kemampuan nyopir lan ngoperasikake mesin.

Gunakake obat kanggo wanita nalika meteng lan laktasi

Kandhutan

Ora ana riset lengkap lan kontrol sing apik kanggo wanita ngandhut. Gunakake Invanz mung nalika meteng yen entuk manfaat luwih saka risiko bisa kedadeyan kanggo ibu lan janin.

Periode nyusoni

Ertapenem diekskresi liwat ASI (pirsani farmakokinetik, distribusi). Ati-ati nalika nggunakake Invanz kanggo ibu sing nyusoni.

Interaksi obat

Nalika nggabungake Ertapenem karo Probenecid, kompetisi Probenecid ndadékaké inhibisi penghapusan aktif Ertapenem liwat tubulus ginjel, saéngga mundhak kanthi sethithik nanging nduweni teges statistik babagan wektu sale (munggah 19%) lan konsentrasi Ertapenem ing awak (25%). Ora perlu nyetel dosis Ertapenem nalika digabungake karo probenecid. Amarga efek sing signifikan ing wektu pembuangan Ertapenem, ora dianjurake kanggo nggunakake Probenecid kanggo nggedhekake wektu semi-sampah Ertapenem.

Panliten in vitro nuduhake yen Ertapenem ora nyandhet transportasi digoxin utawa vinblastin liwat perantara P-Glycoprotein lan Ertapenem dudu substrater sing digunakake ing transportasi P-G. Riset in vitro ing microsom ati wong ketemu sing Ertapenem ora nyandhet metabolisme obatan liyane liwat katalis saka 6-wangun Cytochrom P450 (CYP) utamané: 1A2, 2C9, 2C19, 2D6, 2E1 lan 3A4. Ora mesthi interaksi karo Ertapenem liwat mekanisme nyegah reresik obat liwat p-glikoprotein utawa liwat katalis Cytochrom P450. (Deleng farmakokinetik, distribusi lan metabolisme).

Saliyane Probenecid, durung nganakake studi khusus liyane babagan interaksi klinis.

Artikel babagan literatur babagan kasus individu nuduhake yen panggunaan carbapenem, kalebu Ertapenem bebarengan karo asam Valproic utawa sodium Divalproex bakal nyuda tingkat asam Valproic. Tingkat asam valproat bisa dikurangi luwih murah tinimbang interaksi iki, saéngga nambah risiko serangan kejang. Sanajan mekanisme interaksi iki ora dingerteni, data saka studi kewan lan in vitro nuduhake yen karbapenem bisa nyandhet hidrolisis konversi glukuronida saka asam Valproat (VPA-G) dadi asam Valproat, saengga bisa nyuda tingkat asam Valproat serum (deleng kanthi teliti).

Panyimpenan

Sadurunge rekonsiliasi

Panyimpenan ing Vietnam ing suhu 2 ° C-8 ° C.

solusi reconstituted kanggo transmisi

Sawise rekonsiliasi, encer solusi obat kasebut kanthi langsung nganggo larutan injeksi NaCl 0,9% (deleng dosis lan cara nggunakake, deleng informasi lembar instruksi), lan bisa digunakake sajrone 6 jam nalika disimpen ing suhu kamar (25 ° C) utawa panyimpenan 24 jam ing kulkas kanthi suhu 5 ° C lan digunakake sajrone 4 jam sawise dicopot saka kulkas. Aja beku solusi Invanz.

Obat liyane

Disclaimer

Kabeh upaya wis ditindakake kanggo mesthekake yen informasi sing diwenehake dening Drugslib.com akurat, nganti -tanggal, lan lengkap, nanging ora njamin kanggo efek sing. Informasi obat sing ana ing kene bisa uga sensitif wektu. Informasi Drugslib.com wis diklumpukake kanggo digunakake dening praktisi kesehatan lan konsumen ing Amerika Serikat lan mulane Drugslib.com ora njamin sing nggunakake njaba Amerika Serikat cocok, kajaba khusus dituduhake digunakake. Informasi obat Drugslib.com ora nyetujoni obat, diagnosa pasien utawa menehi rekomendasi terapi. Informasi obat Drugslib.com minangka sumber informasi sing dirancang kanggo mbantu praktisi kesehatan sing dilisensi kanggo ngrawat pasien lan / utawa nglayani konsumen sing ndeleng layanan iki minangka tambahan, lan dudu pengganti, keahlian, katrampilan, kawruh lan pertimbangan babagan perawatan kesehatan. praktisi.

Ora ana bebaya kanggo kombinasi obat utawa obat sing diwenehake kanthi cara apa wae kudu ditafsirake kanggo nuduhake yen obat utawa kombinasi obat kasebut aman, efektif utawa cocok kanggo pasien tartamtu. Drugslib.com ora nanggung tanggung jawab kanggo aspek kesehatan apa wae sing ditindakake kanthi bantuan informasi sing diwenehake Drugslib.com. Informasi sing ana ing kene ora dimaksudake kanggo nyakup kabeh panggunaan, pituduh, pancegahan, bebaya, interaksi obat, reaksi alergi, utawa efek samping. Yen sampeyan duwe pitakon babagan obat sing sampeyan gunakake, takon dhokter, perawat utawa apoteker.